DESIGN AND MOLECULAR DOCKING OF SULFONAMIDE DERIVATIVES

KAMALLOCHAN BARMAN*, GARGI DAS*, JUN MONI KALITA*, PAYAL DASGUPTA*
*Girijananda Chowdhury Institute of Pharmaceutical Science (GIPS), Hatkhowapara, Azara, Guwahati, Assam, India, 781017, Himalayan Pharmacy Institute, Majhitar, East Sikkim, 737136
Email: barmankamallochan@gmail.com
Received: 03 May 2021, Revised and Accepted: 25 Jun 2021

ABSTRACT

Objective: Sulfonamides are a sulfa-related group of antibiotics, which are used to treat bacterial infections and some fungal infections. Some sulfonamides are also devoid of antibacterial activity, such as thiazide diuretics, etc. In this study, an effort was made to find out some novel and potent Sulfonamide derivatives as diuretic agents.

Methods: Here, 30 three-dimensional sulphonamides are designed and docking simulation with PDB ID 1AZM which was downloaded from www.rcsb.org. All the molecules were also screened through a preliminary property filter (Molinspiration Property Calculator).

Results: Among the 30 different molecules designed, 5 molecules were found to have a very good affinity towards the target protein.

Conclusion: These molecular properties define if a molecule can be orally active in our body.

Keywords: Docking, Sulphonamide, SAR

INTRODUCTION

Molecular docking is an attractive scaffold to understand drug biomolecular interactions for the rational drug design and discovery, as well as in the mechanistic study by placing a molecule (ligand) into the preferred binding site of the target-specific region of the DNA/protein (receptor) mainly in a non-covalent fashion to form a stable complex of potential efficacy and more specificity. The information obtained from the docking technique can be used to suggest the binding energy, free energy, and stability of complexes. At present, a docking technique is utilized to predict the tentative binding parameters of the ligand-receptor complex. The main objective of molecular docking is to attain a ligand-receptor complex with optimized conformation and to possess less binding free energy [1, 2].

A sulfonamide is a functional group (a part of a molecule) that is the basis of several groups of drugs, which are called sulphonamides, sulfa drugs, or sulphamides. The original antibacterial sulfonamides are synthetic (non-antibiotic) antimicrobial agents that contain the sulfonamide group. Some sulfonamides are also devoid of antibacterial activity, e.g., the anticonvulsant sulfamide. The sulfonylureas and thiazide diuretics are newer drug groups based upon the antibacterial sulphonamides [3].

The discovery of sulphonamide diuretic i.e., thiazide diuretics in 1957-58 was the beginning of a new era in the treatment of edema and hypertension. In general, diuretics such as carbonic anhydrase inhibitors, thiazides, and loop diuretics are sulfonamide compounds. Loop diuretics are considered safer and high ceiling diuretics. Their efficacy has a linear relationship with their doses, to the contrary of thiazides which are low-ceiling diuretics. These properties can be attributed to the reason that the sulphonamide derivative shows diuretic activity [4, 5].

Thiazides are sulphonamide-related organic acids that are secreted into the proximal tubule by an organic secretory mechanism.

MATERIALS AND METHODS

The various kind of software which are used. Marvin sketch is used to design 2D and 3D structures of molecules as described in table 1. Molinspiration property calculatorb is used to determine the physicochemical property predictions. Arguslab It is used for docking study of the designed molecule.

Table 1: Molecule and the structure

| Molecule | Structures |
|----------|------------|
| S1A      | ![Structure](image1.png) |
| S1B      | ![Structure](image2.png) |
| S1C      | ![Structure](image3.png) |
| S1D      | ![Structure](image4.png) |
| S1E      | ![Structure](image5.png) |
Lipinski’s rule of five also known as Pfizer’s rule of five or simply the Rule of five (RO5) is a rule of thumb to evaluate drug-likeness or determine if a chemical compound with a certain pharmacological or biological activity has properties that would make it a likely orally active drug in humans [6, 7]. Here in the present study, a java-based online platform (molinspiration property calculator) was used to calculate the molecular properties like lipophilicity (miLogP), Total Polar Surface Area (TPSA), No of atoms, Molecular Weight(MW), No. of Oxygen and Nitrogen, No. of OH and NH, and the number of rotatable bonds were predicted.

### Table 2: Predicted physicochemical properties of designed molecules

| Molecule | mi LogP | No. of atoms | M. W.   | No. of O and N | No. of OH and NH | No. of violations |
|----------|---------|--------------|---------|----------------|------------------|------------------|
| S1A      | 1.67    | 19           | 273.31  | 4              | 2                | 0                |
| S1B      | 1.51    | 20           | 285.32  | 4              | 2                | 0                |
| S1C      | 0.20    | 15           | 226.26  | 5              | 3                | 0                |
| S1D      | 1.72    | 17           | 249.29  | 5              | 3                | 0                |
| S1E      | 1.37    | 16           | 254.34  | 4              | 3                | 0                |
| S1F      | 0.92    | 16           | 238.27  | 5              | 3                | 0                |
| S1G      | -0.34   | 12           | 181.22  | 3              | 2                | 0                |
| S1H      | -0.02   | 17           | 250.28  | 6              | 3                | 0                |
| S1I      | 1.62    | 18           | 257.31  | 3              | 2                | 0                |
| S1J      | 2.53    | 17           | 267.74  | 3              | 2                | 0                |
| S1K      | 1.71    | 20           | 293.30  | 7              | 3                | 0                |
| S1L      | 1.52    | 19           | 276.32  | 5              | 3                | 0                |
| S1M      | 2.67    | 17           | 312.19  | 3              | 2                | 0                |
| S1N      | 0.06    | 13           | 197.22  | 4              | 2                | 0                |
| S1O      | 1.74    | 20           | 293.30  | 7              | 3                | 0                |
| S1P      | 0.38    | 16           | 257.34  | 5              | 3                | 0                |
| S1Q      | 0.65    | 18           | 263.32  | 5              | 5                | 0                |
| S1R      | 2.04    | 23           | 329.43  | 5              | 2                | 0                |
| S1S      | 1.98    | 20           | 287.34  | 5              | 4                | 0                |
| S1T      | 2.51    | 17           | 267.74  | 3              | 2                | 0                |
| S1U      | 1.07    | 15           | 240.31  | 4              | 2                | 0                |
| S1V      | 1.26    | 20           | 288.33  | 6              | 3                | 0                |
| S1W      | -0.20   | 18           | 265.30  | 7              | 5                | 0                |
| S1X      | 1.78    | 17           | 248.31  | 4              | 3                | 0                |
| S1Y      | 0.88    | 17           | 249.29  | 5              | 3                | 0                |
| S1Z      | 1.50    | 17           | 252.34  | 4              | 3                | 0                |
| S1Zi     | -0.14   | 13           | 196.23  | 4              | 3                | 0                |
| S1Zii    | 0.24    | 14           | 210.26  | 4              | 3                | 0                |
| S1Ziii   | 0.51    | 15           | 224.28  | 4              | 3                | 0                |
| S1Ziv    | 0.78    | 16           | 238.31  | 4              | 3                | 0                |

Cut off values: miLogP: 5, TPSA: 400 cÅ, MW: 500 Dalton, No of O, N: 10, No of OH, NH: 5, Volume: 800 cÅ.

### Receptor preparation and washing

A structure of sulfonamide drug complexed with human carbonic anhydrase I (PDB entry code: 1AZM) was obtained from a protein data bank provided by www.rcsb.org. Water molecules were removed and ligand and cofactors were allowed to retain. Protein was cleaned to remove any extra conformation and the binding site was analyzed. Finally, the protein was prepared according to the requirements of the docking protocol [8].

Structures of the designed ligands were prepared by the Marvin sketch tool as supported by Sanjeevani online program [9]. Then the 3D structures of the ligands were imported to the Arguslab workplace and energy minimization was done by adding hydrogens and CharmM forcefield. Further possible ligand conformations were generated by considering an in silico pH of 7-7.4 [10, 11].

### Docking

Prepared Ligand was then docked at the active site of the enzyme protein using dock a ligand protocol keeping full flexibility of both the ligand and the protein [12, 13]. A greed consideration of 0.4 Å was applied while docking and the binding energy of the best pose were recorded [14]. Further binding pose of the ligand was refined and the number of hydrogen bonds formed and the amino acid responsible for individual hydrogen bonds was determined [15, 16].
Table 3: Binding energy of docked molecules

| Molecule | (-) Binding energy kcal/mol |
|----------|-----------------------------|
| S1A      | 9.85                        |
| S1P      | 9.32                        |
| S1H      | 9.10                        |
| S1F      | 9.09                        |
| S1K      | 9.04                        |
| S1W      | 9.02                        |
| S1N      | 8.90                        |
| S1C      | 8.87                        |
| S1G      | 8.80                        |
| S1M      | 8.79                        |
| S1I      | 8.70                        |
| S1J      | 8.69                        |
| S1T      | 8.69                        |
| S1B      | 8.55                        |
| S1Z      | 8.53                        |
| S1X      | 8.50                        |
| S1Y      | 8.49                        |
| S1Zi     | 8.44                        |
| S1Zii    | 8.33                        |
| S1Q      | 8.32                        |
| S1Ziv    | 8.24                        |
| S1E      | 8.24                        |
| S1S      | 8.05                        |
| S1U      | 8.02                        |
| S1Ziii   | 7.79                        |
| S1D      | 7.28                        |
| S1L      | -                           |
| S1O      | -                           |
| S1R      | -                           |
| S1V      | -                           |

RESULTS AND DISCUSSION

The present study results in a systematic and rational plan of work that was carried out to overcome the different problems of the classical approach of drug discovery. Among the 30 different molecules designed, 5 molecules were found to have a very good affinity towards the target protein as shown in fig. 1 to fig. 5. The binding pose of the 5 probable active molecules is depicted below.

CONCLUSION

In the present study, an effort was made to find out some novel and potent sulfonamide derivatives as diuretic agents. Arguslab, a free to user software was used to dock the designed molecules at the enzyme active site. The three-dimensional enzyme (Carbonic anhydrase I) with PDB ID 1AZM was downloaded from https://www.rcsb.org and used for the docking studies. All the molecules were also screened through a preliminary property filter (Molinspiration Property Calculator), where certain molecular properties like Molecular Weight, LogP value, No of Hydrogen Bond Donor, No of Hydrogen Bond Acceptor, TPSA, and No of Atoms were calculated. These molecular properties define if a molecule can be orally active in our body.

Out of 30 designed molecules, five designed molecules viz. S1A, S1P, S1H, S1F, and S1K were found to be active and can be used for further studies.

ACKNOWLEDGEMENT

Conflict of Interest: No conflict of Interest
FUNDING
Nil

AUTHORS CONTRIBUTIONS
All the authors have contributed equally.

CONFLICT OF INTERESTS
Declared none

REFERENCES
1. Abagyan R, Totrov M, Kuznetsov D. ICM-a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comp Chem 1994;15:488-506.
2. Rangaraju A, Rao AV. A review on molecular docking-novel tool in drug design and analysis. J Hormo Res Pharm 2013;2:215-21.
3. Agarwal S, Mehrotra R. An overview of molecular docking. JSM Chem 2016;4:1024.
4. Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules 2015;20:13384-421.
5. Henry RJ. The mode of action of sulfonamides. Bacteriol Rev 1943;7:175-262.
6. Wilson and Grisvold’s. Text Book of Organic Medical and Pharmaceutical Chemistry; 2010. p. 242.
7. Pandey SN. A Text book of Medicinal Chemistry Vol I and Vol II; 2013. p. 189.
8. Claudia T, Alessandro C. Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited. Org Biomol Chem 2008;6:2499.
9. Jorge RA, Camí, gerardo enrique; a structural and analogue of acetazolamide, show interesting carbonic anhydrase inhibitory properties. J Enzyme Inhib Med Chem 2015;31:1102-10.
10. Logemann W, Giraldi PN. Sulphonamides with diuretic activity. Nature 1959;184:1711.
11. Christopher A Lipinski, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001;46:3-26.
12. Christopher A Lipinski. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technol 2004;1:337-41.
13. Tudor I Oprea, Andrew M Davis, Simon J Teague, Paul D Leeson. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Computer Sci 2001;41:1308-15.
14. Paul D Leeson, Brian Springthorpe. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discovery 2007;6:881–90.
15. Krovat EM, Steindl T, Langer T. Recent advances in docking and scoring. Curr Computer-Aided Drug Design 2005;1:93-102.
16. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discovery 2004;3:935-49.